<DOC>
	<DOCNO>NCT00936988</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm , extension study design evaluate long-term tolerability , safety , efficacy cinacalcet . Subjects enrol immediately complete parent study , 990120 . All subject begin treatment 30 mg cinacalcet twice daily ( BID ) , dose adjustment make per protocol-specified guideline . The study consist 2 consecutive phase occur follow order : dose-titration phase last 12 week maintenance phase last approximately 4Â½ year .</brief_summary>
	<brief_title>A Multicenter , Open-label Extension Study Assess Long-term Safety Efficacy Oral Calcimimetic Agent AMG 073 ( Cinacalcet ) Primary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<mesh_term>Calcimimetic Agents</mesh_term>
	<criteria>Successfully complete parent study 990120 Agreed use highly effective ( opinion principal investigator ) contraceptive measure throughout study Were able comprehend willing give write informed consent participation study Pregnant breastfeeding Had psychiatric disorder interfere understanding give informed consent compliance protocol requirement Had condition reduce chance obtain data ( eg , know poor compliance ) Participating another investigational study time study entry Had unstable medical condition , define hospitalize within 28 day day 1 , otherwise unstable judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hyperparathyroidism , Primary</keyword>
	<keyword>cinacalcet</keyword>
</DOC>